Sichuan Kelun Pharmaceutical Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Sichuan Kelun Pharmaceutical is de winst gegroeid met een gemiddeld jaarlijks percentage van 30.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 9%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 6.8% per jaar. Het rendement op eigen vermogen van Sichuan Kelun Pharmaceutical is 13.1%, en het heeft een nettomarge van 13.2%.

Belangrijke informatie

30.9%

Groei van de winst

29.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	10.9%
Inkomstengroei	6.8%
Rendement op eigen vermogen	13.1%
Nettomarge	13.2%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

May 02

Recent updates

Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet

Oct 28

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement

Sep 22

Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Aug 16

Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Jul 12

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

Jun 11

An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

May 21

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

May 02

If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Mar 19

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Mar 04

These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Feb 27

Opbrengsten en kosten

Hoe Sichuan Kelun Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SZSE:002422 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	22,500	2,964	5,266	1,862
30 Jun 24	22,482	2,852	5,465	1,946
31 Mar 24	22,035	2,668	5,650	1,955
31 Dec 23	21,454	2,456	5,628	1,944
30 Sep 23	20,841	2,263	5,447	2,256
30 Jun 23	20,712	2,241	5,540	2,037
31 Mar 23	20,194	2,228	5,625	1,870
01 Jan 23	19,038	1,705	5,707	1,795
30 Sep 22	18,531	1,660	5,548	1,752
30 Jun 22	18,170	1,478	5,720	1,805
31 Mar 22	17,608	1,218	5,874	1,735
01 Jan 22	17,277	1,103	5,913	1,737
30 Sep 21	17,487	1,176	5,868	1,717
30 Jun 21	17,465	1,119	6,058	1,608
31 Mar 21	17,078	983	5,953	1,620
31 Dec 20	16,464	829	5,651	1,527
30 Sep 20	16,342	525	6,414	1,503
30 Jun 20	15,945	412	6,525	1,443
31 Mar 20	16,886	624	7,157	1,358
31 Dec 19	17,636	938	7,576	1,286
30 Sep 19	17,078	1,104	7,493	1,070
30 Jun 19	17,482	1,167	7,588	1,048
31 Mar 19	16,708	1,165	7,020	968
31 Dec 18	16,352	1,213	6,839	909
30 Sep 18	15,757	1,384	6,587	866
30 Jun 18	14,285	1,265	5,322	1,102
31 Mar 18	12,933	938	4,677	906
31 Dec 17	11,435	748	3,854	712
30 Sep 17	10,223	434	3,005	467
30 Jun 17	9,412	455	2,961	0
31 Mar 17	8,996	569	2,678	0
31 Dec 16	8,566	585	2,501	0
30 Sep 16	8,198	632	2,264	0
30 Jun 16	8,024	622	2,235	0
31 Mar 16	7,875	648	2,114	0
31 Dec 15	7,763	645	2,056	0
30 Sep 15	7,856	727	1,866	0
30 Jun 15	7,892	874	1,780	0
31 Mar 15	7,976	980	1,788	0
31 Dec 14	8,023	1,002	1,771	0
30 Sep 14	7,888	1,057	1,754	0
30 Jun 14	7,617	1,082	1,659	0
31 Mar 14	7,310	1,101	1,588	0
31 Dec 13	6,831	1,080	1,499	0

Kwaliteitswinsten: 002422 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (13.2%) 002422 } zijn hoger dan vorig jaar (10.9%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 002422 is de afgelopen 5 jaar aanzienlijk gegroeid met 30.9% per jaar.

Versnelling van de groei: De winstgroei van 002422 over het afgelopen jaar ( 31% ) overtreft het 5-jarig gemiddelde ( 30.9% per jaar).

Winst versus industrie: De winstgroei 002422 over het afgelopen jaar ( 31% ) overtrof de Pharmaceuticals -sector -1.2%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 13.1% ) van 002422 wordt als laag beschouwd.

Sichuan Kelun Pharmaceutical Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Sichuan Kelun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings released: EPS: CN¥1.69 (vs CN¥1.22 in FY 2022)

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet

Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2024 Interim Profit Distribution Plan to Be Implemented (A Shares), Payable on 23 October 2024

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 22%

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for the First Half of 2024

Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Sichuan Kelun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings released: EPS: CN¥1.69 (vs CN¥1.22 in FY 2022)

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Investor sentiment improves as stock rises 15%

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 10% to CN¥35.67

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to CN¥32.33

Price target increased by 14% to CN¥29.33

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Cash Dividend on Share A for 2022, Payable on May 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Price target increased to CN¥23.70

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

High number of new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to CN¥22.03

Price target increased to CN¥23.50

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Final Distribution for the Year 2021, Payable on 16 May 2022

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS misses analyst expectations

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) announces an Equity Buyback for CNY 200 million worth of its shares.

High number of new directors

Sichuan Kelun Pharmaceutical Co., Ltd., Annual General Meeting, May 05, 2022

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.10 in 2Q 2020)

Price target decreased to CN¥22.47

Sichuan Kelun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 3 billion in funding

Consensus EPS estimates fall to CN¥0.72

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.58 (vs CN¥0.66 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥21.88

Analysts lower EPS estimates to CN¥0.56

New 90-day low: CN¥18.06

Price target lowered to CN¥25.97

New 90-day low: CN¥20.47

New 90-day low: CN¥21.62

Earnings beat expectations, revenue disappoints

Third quarter earnings released

Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun) entered into an agreement to acquire Shanghai Century Acquisition Corporation (Amex: SHA) in a reverse merger transaction.

First half earnings released

Analysts lower revenue estimates to CN¥16.6b